[Significance of determination of lipid-oxidizing catalytic antibodies in patients with ischemic heart diseases].
From the previously examined patients with ischemic heart disease (IHD), the authors formed two groups in whom an original method was used to detect the abnormal lipid-oxidizing anti-Chlamydia antibodies abzymes that increased the serum concentration of malondialdehyde. The effects of the statin rosuvastatin and the antioxidant licopin on abzymes were comparatively studied. Despite the positive impact of therapy with rosuvastatin on lipid metabolism of IHD patients, the agent exerted no effect on the rate of lipid peroxidation and the activity of lipid-oxidizing antibodies. Licopin intake caused statistically significant lipid metabolic changes in patients with IHD. The antioxidant activity of licopin neutralized the pathogenic effect of lipid-oxidizing anti-Chlamydia abzymes.